Eurand’s Diffucaps® technology enables the development of once-daily controlled-release (CR) capsules or patient-friendly orally disintegrating tablet ( ODT). Download scientific diagram | ORBEXA ® Technology 3) DIFFUCAPS ® Technology: Diffucaps is a multiparticulate bead system comprised of multiple layers of. DIFFUCAPS ® technology 4) DIFFUTAB ® Technology: Diffutab technology enables customized release profiles and region-specific delivery. Diffutab.
|Published (Last):||7 March 2012|
|PDF File Size:||12.2 Mb|
|ePub File Size:||9.63 Mb|
|Price:||Free* [*Free Regsitration Required]|
Electrothermally activated microchips for implantable drug delivery and biosensing. Magnetically triggered reversible controlled drug delivery from microfabricated polymeric multireservoir devices ; The release is controlled by the nature of the drug-containing bead matrix or its semi-permeable membrane coating.
Targeting a drug to a distal organ of techbology tract GITlike the colon, requires that the release is prevented in the two-third portion of the GIT.
Osmosis An osmotic pressure can be built up within the interior of the particle when water allows entering under the right circumstances. The inflamed responsive cells produce hydroxyl radicals.
PRODAS technology is a combination of both Multiparticulate and hydrophilic matrix tablet technologies in which a number of minitablets gathered in a hard gelatine capsule. As different pH environment exist at different parts of the gastrointestinal tract so this advantage is utilised by pH dependent system.
Eurand applied this technology to both soluble and insoluble products.
9. Pulsatile Drug Delivery System: Method and Technology Review | Insight Medical Publishing
Externally regulated pulsatile release system Electroresponsive pulsatile release An electric field as an external stimulus has advantages, such as availability of equipment that allows precise control with regard to the magnitude of the current, duration of electric pulses, interval between teechnology, etc. Int J Pharm Res Devel. Sulfonylurea, Insulin Arthritis Level of pain increases at night.
Positive thermosensitive pulsatile drug release using negative thermosensitive hydrogels.
Diffucaps® Customized Release Technology | Adare Pharmaceuticals | CPhI Online
European Journal of Pharmaceutical Sciences ; A new concept of chronopharmaceutics has emerged, wherein research is devoted to the design and evaluate the drug delivery systems that release a therapeutic agent at a rhythm that ideally matches the biological requirement of a given disease therapy2.
In this System, a capsule coated with semi permeable membrane is employed Figure. A layer of organic acid or alkaline buffer surrounds the beads to direct solubility of a poorly soluble drug by creating an optimal pH microenvironment Figure As degradation of biodegradable matrix was enhanced by ultrasonic exposure, the rate of drug yechnology also increased. In this graph, it was aimed to achieve a sigmoid release pattern Figure 1.
This deviation from normal range acts as a stimulus that triggers the release of therapeutic agents from several temperature-responsive drug delivery systems. Diseases that require pulsatile drug delivery. Current status of drug delivery technologies and future directions. Complex oral technologh forms were fabricated with 3DP to show lagged release, extended release, double release and zero-order release.
Diffucaps Customized Release Technology from Adare Pharmaceuticals
The drug is forced out of the particle into the exterior through the coating. In these systems, the drug is released after stimulation by any biological factor, like temperature or any other chemical stimuli.
Magnetic modulation of release of macromolecules from polymers. In case of cardiovascular diseases, BP is at its lowest during the sleep cycle and rises steeply during the early morning period. Ultradian Rhythms Shorter duration oscillations are termed as Ultradian Rhythms more than one cycle per 24 h. Glucose-responsive insulin release devices These devices have been developed to respond with changes in glucose concentration in the blood.
Ritalin methyl phenidate used in the treatment of attention deficit hyper active disorder ADHD in children4,8,9,11,13,14,15,16, Formulation and evaluation of chronopharmaceutical drug delivery of theophylline for nocturnal asthma. These systems are beneficial for drugs with chronopharmacological behavior, where nocturnal dosing is required, and for drugs that show the first-pass effect. Chronotherapy technolgoy an example of when drug release may be programmed to occur after a prolonged interval following administration.
Diffucaps® Customized Release Technology
Electroactive controlled release thin films. Gastro retentive drug delivery system is a suggestion to prolong gastric residence time, thereby targeting site-specific drug release in upper gastrointestinal GI tract.
Thermosensitive hydrogels have been investigated as possible drug delivery carriers for stimuli-responsive drug delivery. The lag time is essential for drugs that undergo degradation in gastric acidic medium e. Scherer International Corporation, Michigan developed the diffkcaps system, in which the lag time is continued by a plug that gets pushed away by swelling or erosion, releasing the drug as a pulse from the insoluble diffucqps body.
The hydro gels showed a glucose-responsive, sol—gel phase transition dependent upon the external glucose concentration. But major drawbacks arise from the biological variations among individuals.
The central pathophysiology of epilepsy and the behavioral classification of convulsive events.